Mirdametinib in Patients With Advanced NF1-mutant Melanoma

This study is testing a drug called mirdametinib — which targets a specific mutation (NF1) in tumor cells — for people with advanced melanoma (skin cancer that has spread or cannot be removed) that carries an NF1 gene mutation. **You may be eligible if...** - You have unresectable or metastatic melanoma with a confirmed NF1 mutation (tested in a certified lab) - You have previously been treated with standard immunotherapy drugs (anti-PD-1 and anti-CTLA-4), unless they were not appropriate for you - Your cancer is currently growing **You may NOT be eligible if...** - Your NF1 gene change is of unknown significance - You have not received prior immunotherapy (unless it was not clinically suitable) - You are in poor overall health Talk to your doctor to see if this trial is right for you.